Cell Signaling Technology Announces a Research Project with Bristol-Myers Squibb Company for the Evaluation of CST's PhosphoScan(R) Platform for Kinase Inhibitor Proteomic Profiling.DANVERS, Mass. -- Cell Signaling Cell signaling is part of a complex system of communication that governs basic cellular activities and coordinates cell actions. The ability of cells to perceive and correctly respond to their microenvironment is the basis of development, tissue repair, and immunity as well as Technology, Inc. (CST CST abbr. 1. Central Standard Time 2. convulsive shock treatment CST Central Standard Time Noun 1. ) announced today an agreement with Bristol-Myers Squibb Bristol-Myers Squibb (NYSE: BMY), colloquially referred to as BMS, is a pharmaceutical corporation, formed by a 1989 merger between pharmaceutical companies Bristol-Myers Company, founded in 1887 by William McLaren Bristol and John Ripley Myers in Clinton, NY (both were Company (BMS BMS abbr. Bachelor of Marine Science ) under which it will perform a phosphoproteomic research project employing its PhosphoScan([R]) technology to provide BMS with cellular phospho-profiles of a small-molecule kinase inhibitor. The research project will enable BMS to evaluate CST's PhosphoScan([R]) technology. PhosphoScan([R]) proteomics is a patent-pending technology that enables the discovery of cell and tissue phospho-profiles (Phospho-Signatures[TM]), and the quantification of inhibitor-response profiles. The PhosphoScan([R]) strategy involves immunoaffinity purification and tandem mass spectroscopy mass spectroscope n. Any of various devices that use magnetic fields, electric fields, or both to determine the masses of isotopes in a sample by producing a mass spectrum. , and it was first described in the journal Nature Biotechnology Nature Biotechnology (Nat Biotechnol; ISSN 1087-0156) is an academic journal covering the science and business of biotechnology. Nature Biotechnology is a continuation of Bio/technology (Biotechnology (NY) , Rush J. et al, Nat. Biotechnol. 23, 94-101 (2005). The Phospho-Signatures[TM] discovered with PhosphoScan([R]) may enable the development of biomarker assays for use in the clinical development of a particular therapeutic kinase inhibitor. "We are glad to be working with BMS and this research project is a great opportunity to demonstrate the utility of the PhosphoScan([R]) technology," said Christopher Bunker, CST's Director of Business Development. "PhosphoScan([R]) is a particularly powerful tool when used to quantify changes in cellular phospho-profiles resulting from targeted small molecule treatment." About Cell Signaling Technology, Inc. Cell Signaling Technology, Inc. has expertise and the market leadership position in the development and commercialization of phospho-specific antibodies and assays for kinase and pathway analysis. CST's phospho-specific antibodies are validated in multiple assay platforms and are critical reagents in all stages of pharmaceutical drug discovery and development. PhosphoScan([R]) leverages CST's core capabilities in antibody development to deliver insight into cellular phosphorylation phosphorylation, chemical process in which a phosphate group is added to an organic molecule. In living cells phosphorylation is associated with respiration, which takes place in the cell's mitochondria, and photosynthesis, which takes place in the chloroplasts. profiles enabling more efficient and informative kinase drug discovery and clinical development. CST is commercializing the PhosphoScan([R]) technology through research alliances and licensing opportunities. Information on CST can be obtained at the Company's website at www.cellsignal.com. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion